SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745750.
  • 2
    El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817823.
  • 3
    Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(suppl 1): S5S16.
  • 4
    Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331338.
  • 5
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693699.
  • 6
    Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 10801086.
  • 7
    Stone MJ, Klintmalm GB, Polter D, Husberg BS, Mennel RG, Ramsay MA, et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology 1993; 104: 196202.
  • 8
    Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235: 533539.
  • 9
    Cherqui D. Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998; 5: 3540.
  • 10
    Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005; 11: 497503.
  • 11
    Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11: 14201425.
  • 12
    Jiménez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 2004; 8: 243248.
  • 13
    Stippel DL, Kasper HU, Schleimer K, Töx U, Bangard C, Hölscher AH, et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 2005; 37: 21852187.
  • 14
    Nocera A, Andorno E, Tagloamacco A, Morelli N, Bottino G, Ravazzoni F, et al. Sirolimus therapy in liver transplant patients: an initial experience at a single center. Transplant Proc 2008; 40: 19501952.
  • 15
    Rizell M, Anderson M, Cahlin C, Hafstrom L, Olausson M, Lindner P. Effects of mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008; 13: 6670.
  • 16
    Klintmalm GB, Busuttil RW. The recipient hepatectomy and grafting. In: BusuttilRW, KlintmalmGB, eds. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2005: 575587.
  • 17
    Molmenti EP, Klintmalm GB. Liver transplantation in association with hepatocellular carcinoma: an update of the International Tumor Registry. Liver Transpl 2002; 8: 736748.
  • 18
    Marelli L, Grasso A, Pleguezuelo M, Martines H, Stigliano R, Dhillon AP, et al. Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann Surg Oncol 2008; 15: 35033511.
  • 19
    Decaens T, Roudot-Thoraval F, Badran H, Meyer C, Durand F, Adam R, et al. Liver transplantation for hepatocellular carcinoma: validation of a new prognostic score predicting disease-free survival [abstract]. J Hepatol 2007; 46: S25.
  • 20
    Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 3543.
  • 21
    Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128135.
  • 22
    Guba M, Koehl GE, Neppl E, Doenecke A, Steinbauer M, Schlitt HJ, et al. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int 2005; 18: 8994.
  • 23
    Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 6571.
  • 24
    Tong AW, Su D, Mues G, Tillery GW, Goldstein R, Klintmalm G, et al. Chemosensitization of human hepatocellular carcinoma cells with cyclosporin A in post-liver transplant patient plasma. Clin Cancer Res 1996; 2: 531539.
  • 25
    Chinnakotla S, Goldstein RM, Orr D, Davis GL, Narasimhan G, Uemura T, et al. Pattern of recurrence of hepatocellular carcinoma after liver transplantation [abstract]. Am J Transplant 2006; 6(suppl 2): 330.
  • 26
    Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 13011311.
  • 27
    Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 11621168.
  • 28
    Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol 2006; 12: 31143118.
  • 29
    Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, et al. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633638.
  • 30
    Edwards EB, Harper AM, Freeman RB. The effect of pre-transplant ablation therapy on post-transplant outcome in liver recipients with hepatocellular carcinoma [abstract]. Am J Transplant 2008; 8(suppl 2): 267.
  • 31
    Geissler EK, Schnitzbauer A, Lamby P, Mutzbauer I, Zuelke C, Schlitt HJ. The Silver study: an investigator-initiated trial to determine if sirolimus use improves HCC recurrence free survival in affected liver transplant recipients [abstract]. Am J Transplant 2009; 9(suppl 2): 443.